OncoCyte (LTS:0KCC) ROCE % : -42.14% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is OncoCyte ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OncoCyte's annualized ROCE % for the quarter that ended in Dec. 2023 was -42.14%.

OncoCyte ROCE % Historical Data

The historical data trend for OncoCyte's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte ROCE % Chart

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-112.96

-75.59

-54.89

-15.88

-31.86

OncoCyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															14.79	29.59	-31.42	-26.70	-42.14

OncoCyte ROCE % Calculation

OncoCyte's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-24.803	/	( ( (100.091 - 12.106)	+	(74.892 - 7.194) )	/ 2 )
	=	-24.803	/	( (87.985	+	67.698)	/ 2 )
	=	-24.803	/	77.8415
	=	-31.86 %

OncoCyte's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-29.764	/	( ( (81.587 - 8.033)	+	(74.892 - 7.194) )	/ 2 )
	=	-29.764	/	( ( 73.554	+	67.698 )	/ 2 )
	=	-29.764	/	70.626
	=	-42.14 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

OncoCyte (LTS:0KCC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OncoCyte ROCE % Related Terms

Thank you for viewing the detailed overview of OncoCyte's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (LTS:0KCC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (LTS:0KCC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OCX:USA

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (LTS:0KCC) Headlines

No Headlines